Intelligent Bio Solutions (INBS) AI Stock Analysis

• Market Cap: $10.17M
• Dividend Yield: N/A
• Average Volume (3M): 225.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.94
• Revenue Growth: -1.90%
• EPS Growth: 87.72%
• Country: US
• Employees: 50
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.36
• Shares Outstanding: 9,077,326
• 10 Day Avg. Volume: 422,780
• 30 Day Avg. Volume: 225,904
• PEG Ratio: 0.01
• Price to Book (P/B): 3.03
• Price to Sales (P/S): 2.97
• P/FCF Ratio: -0.92
• Enterprise Value/Market Cap: 1.15
• Enterprise Value/Revenue: 3.82
• Enterprise Value/Gross Profit: 9.36
• Enterprise Value/Ebitda: -1.25
• 1Y Price Target: $1.00
• Price Target Upside: -10.71% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: $1.00 ▼(-10.71% Downside)

The overall stock score is heavily influenced by the company's weak financial performance, characterized by consistent losses and negative cash flows. Technical analysis also indicates bearish momentum, further contributing to a low score. The valuation is challenging due to a negative P/E ratio and lack of dividend yield, providing little incentive for investors.

Intelligent Bio Solutions Business Overview & Revenue Model

Company Description

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

How the Company Makes Money

Intelligent Bio Solutions generates revenue through multiple streams, primarily by selling its diagnostic testing devices and associated consumables to healthcare providers, laboratories, and research institutions. The company also earns income through licensing agreements for its proprietary technology to other firms in the healthcare sector. Additionally, INBS engages in collaborative partnerships with pharmaceutical companies and research organizations, which can provide funding for product development and market expansion. Grant funding from government and non-profit organizations for research and development initiatives also contributes to the company's earnings.

Intelligent Bio Solutions Financial Statement Overview

Summary

Intelligent Bio Solutions faces significant financial challenges, with consistent losses and negative cash flows. While leverage is low, the company struggles with profitability and efficient capital utilization. The financial health is precarious, requiring strategic improvements to achieve stability and growth.

Income Statement

The company has shown some revenue growth, but profitability remains a significant issue with consistently negative net profit margins and EBIT margins. The gross profit margin has decreased over the years, indicating potential challenges in cost management or pricing power.

Balance Sheet

The debt-to-equity ratio is low, suggesting limited leverage, which is positive. However, the return on equity is negative, indicating that the company is not generating sufficient returns on shareholder investments. The equity ratio is moderate, reflecting a balanced capital structure.

Cash Flow

The company has negative operating and free cash flows, which is concerning. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is somewhat aligned with net income, but both are negative. Cash flow growth rates are volatile, reflecting operational challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.05M	3.05M	3.11M	1.26M	0.00	1.98M
Gross Profit	1.25M	1.25M	1.43M	326.67K	0.00	1.98M
EBITDA	-9.33M	-9.34M	-8.81M	-9.47M	30.82K	-1.82M
Net Income	-10.57M	-10.57M	-10.16M	-10.63M	-8.31M	-7.04M
Balance Sheet
Total Assets	8.25M	8.25M	13.78M	10.35M	12.35M	20.40M
Cash, Cash Equivalents and Short-Term Investments	1.02M	1.02M	6.30M	1.54M	8.24M	12.57M
Total Debt	281.81K	281.81K	871.44K	1.34M	0.00	0.00
Total Liabilities	5.44M	5.44M	5.60M	6.67M	5.81M	6.85M
Stockholders Equity	3.00M	3.00M	8.33M	3.80M	6.62M	13.61M
Cash Flow
Free Cash Flow	-9.91M	-9.91M	-9.79M	-7.88M	-3.74M	-11.30M
Operating Cash Flow	-9.68M	-9.68M	-9.57M	-7.38M	-3.36M	-11.30M
Investing Cash Flow	-231.84K	-231.84K	-221.43K	-694.14K	-880.22K	0.00
Financing Cash Flow	4.60M	4.60M	14.56M	1.44M	0.00	23.40M

Intelligent Bio Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Negative. The current price of 1.12 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.58, and below the 200-day MA of 1.63, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 32.39 is Neutral, neither overbought nor oversold. The STOCH value of 7.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBS.

Intelligent Bio Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	62 Neutral	$28.21M	-14.40	-35.47%	―	27.05%	55.03%
MYNZ	44 Neutral	$7.10M	―	-358.07%	―	―	―
INBS	38 Underperform	$10.17M	―	-186.64%	―	-1.90%	87.72%
BIAF	38 Underperform	$7.08M	-0.25	547.20%	―	4.99%	22.58%
CHEK	26 Underperform	$15.52M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Intelligent Bio Solutions Corporate Events

Intelligent Bio Solutions Submits Key FDA Information

On August 6, 2025, Intelligent Bio Solutions Inc. announced the submission of additional information to the FDA as part of its 510(k) clearance process, aiming for U.S. market entry later in the year. The submission includes extensive cybersecurity and performance data, reinforcing the company’s fingerprint sweat-based drug screening technology. This move is a critical step in the company’s U.S. expansion strategy, with the potential to significantly impact its market presence and commercial opportunities in the multi-billion-dollar U.S. market. The company expects a response from the FDA within six weeks.

Intelligent Bio Solutions Raises $3.8M Through Warrant Deals

On July 25, 2025, Intelligent Bio Solutions Inc. entered into inducement agreements with existing warrant holders to raise approximately $3.8 million in gross proceeds. The agreements involve the exercise or prepayment of Series G and Series H-1 warrants at a reduced price, with the issuance of new Series J warrants. The proceeds will fund the completion of the company’s 510k filing with the U.S. FDA for its Fingerprint Drug Screening System and support working capital and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the transaction, which is expected to close around July 28, 2025.

Intelligent Bio Solutions Advances Fingerprinting System for FDA

On July 23, 2025, Intelligent Bio Solutions Inc. announced the successful collection of new data that enhances the security and performance of its Intelligent Fingerprinting Drug Screening System, bolstering its FDA 510(k) submission. The company completed rigorous testing to validate the system’s resilience and accuracy, positioning it strongly for FDA clearance. This advancement supports the company’s goal to enter the U.S. market in 2025 and expand its international operations, addressing the growing demand for workplace safety solutions.

Intelligent Bio Solutions Announces Global Distribution Deal

On July 16, 2025, Intelligent Bio Solutions Inc. announced a global distribution agreement with Smartox LLC to introduce its SmarTest Patch drug detection product to international markets outside the U.S. and Canada. This partnership strengthens the company’s position in non-invasive drug testing solutions and aligns with its international growth strategy, opening new opportunities in the justice and rehabilitation sectors. The global drug testing market is projected to grow significantly, and this agreement provides an additional revenue stream for Intelligent Bio Solutions. The company is also focused on securing FDA clearance for its fingerprint sweat-based drug testing technology to expand its U.S. market presence.

Intelligent Bio Solutions Launches SmarTest Patch for Drug Testing

On July 15, 2025, Intelligent Bio Solutions Inc. announced the addition of the SmarTest® Patch to its non-invasive drug testing solutions portfolio. This innovative wearable device, developed by SMARTOX®, allows for continuous drug detection through sweat over a 7 to 10-day period. The SmarTest Patch complements the company’s existing Intelligent Fingerprinting Drug Testing Solution, enhancing its product offerings and market position in non-invasive testing technologies. The new device is expected to open opportunities in markets requiring longer detection windows, particularly in justice and rehabilitation settings, thereby strengthening the company’s position as demand for non-invasive drug testing options grows.